Best practices in toxicology: Current perspectives for enhancing drug safety

Putting patient safety at the forefront

Drug development is an increasingly expensive business and so companies need to identify strategies to improve the economics of pharma R&D. Unanticipated preclinical toxicity and adverse events in the clinical stage are leading causes of drug attrition, directly contributing to the rapidly increasing costs of drug development, as well as potentially putting patient safety at risk.

In this paper, Clarivate experts highlight some of the approaches that companies can employ to identify potential safety signals early on in the drug discovery and development process. This report explores toxicology best practices including: